Small-Molecule NPRA Agonists for Sustained Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiometabolic diseases such as high blood pressure, heart failure, kidney disease, and diabetes face challenges due to the short half-lives and complex processing of peptide hormones like ANP and BNP, limiting sustained activation of Natriuretic Peptide Receptor A (NPRA).
Innovation Solution
Development of small molecule NPRA agonists, represented by compounds of Formula I, which can activate NPRA over extended periods, mimicking the beneficial effects of natriuretic peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide hormones (ANP, BNP) are used to activate NPRA, then beneficial therapeutic effects are achieved, but the treatment duration is limited due to short half-lives (2 to 20 min)
Solution Approach 1:
The patent creates small molecule copies that mimic the structure and function of peptide hormones ANP and BNP. These small molecule agonists replicate the NPRA activation capability of the natural peptides but with dramatically improved pharmacokinetic properties, including extended half-life and oral bioavailability, thereby resolving the contradiction between therapeutic efficacy and duration of action
Solution Approach 2:
The invention changes the chemical parameters from peptide-based structures to small molecule structures. This parameter change transforms the pharmacokinetic profile, extending the half-life from minutes to hours while maintaining NPRA activation potency, thus achieving both reliable therapeutic effects and sustained duration of action
2Reliability
If peptide hormones are used for NPRA activation, then therapeutic benefits are obtained, but complex processing and clearance in local tissues complicate the treatment
Solution Approach 1:
By creating small molecule copies instead of using complex peptide structures, the patent simplifies the chemical processing requirements. Small molecules are more stable, require less complex metabolic processing, and have predictable clearance pathways compared to peptide hormones, thereby reducing treatment complexity while maintaining therapeutic reliability
Solution Approach 2:
The small molecule agonists are designed to be stable, orally available compounds that do not require complex parenteral administration or specialized handling. Their simplified pharmacokinetic profile eliminates the need for complex processing and monitoring systems required for peptide hormones, reducing overall treatment complexity
3Duration of action of moving object
If small molecule NPRA agonists are developed, then sustained activation of NPRA is achieved, but new compound structures must be synthesized and validated
Solution Approach 1:
The patent employs systematic parameter changes in molecular structure design, exploring various core structures (e.g., indole, pyridine, piperidine substitutions) and functional groups to optimize both duration of action and manufacturability. This structured approach to parameter optimization balances the need for sustained activation with practical synthesis considerations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The small molecule NPRA agonists provide effective treatment and prevention for cardiometabolic diseases by sustained activation of NPRA, addressing the limitations of peptide hormones.
Implementation Method 1
The peptide hormone Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), secreted from heart, and their homolog urodilatin (URO), secreted from vasculature and kidney, all activate NPRA to stimulate the production of cyclic guanosine monophosphate (cGMP)
Data Source
AI summary
The present invention relates to Compounds of Formula I:and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.